Literature DB >> 34326501

Clinical evaluation of torpedo maculopathy in an infant population with additional genetic testing for NEXMIF mutation.

Gokhan Celik1, Murat Gunay2, Asli Vural3, Osman Kizilay4, Yasemin Kendir Demirkol5, Muhammet Kazim Erol6.   

Abstract

PURPOSE: To assess clinical characteristics of torpedo maculopathy (TM) lesions in an infant population with age ≤1.5 years and to investigate the role of NEXMIF mutation in the development of TM.
METHODS: Retrospective analysis of medical records of 17 consecutive infants with the diagnosis of TM between 2016 January and 2019 December were done. Fundus images and a hand-held spectral-domain optical coherence tomography (Envisu 2300, Bioptigen, Morrisville, NC, USA) were used to identify clinical characteristics of TM lesions. Additional molecular testing for mutation screening for NEXMIF gene was also carried out.
RESULTS: Totally 55334 infants were screened during the study period and 17 (0.03%) were identified as having TM. The mean age at the time of diagnosis was 3.94±5.08 months. All TM lesions showed variable degrees of hypopigmentation. Satellite lesion in one infant was nasally located to the main TM lesion. Absence, disruption, loss, degeneration and/or irregularity of the ellipsoid zone were common findings on OCT examination. No pathogenic or likely pathogenic variant of NEXMIF gene was detected.
CONCLUSION: Fundoscopic appearance and OCT findings of lesions show similarities to those already reported previously. Contrary to popular belief, a nasally located satellite lesion was observed in one of our case.
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34326501      PMCID: PMC9307558          DOI: 10.1038/s41433-021-01714-8

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   4.456


  25 in total

1.  Torpedo maculopathy at the site of the fetal "bulge".

Authors:  Carol L Shields; Juan M Guzman; Michael J Shapiro; Lisa E Fogel; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2010-04

2.  Oct findings in torpedo maculopathy.

Authors:  María R Sanabria; Rosa M Coco; María Sanchidrian
Journal:  Retin Cases Brief Rep       Date:  2008

3.  Torpedo Maculopathy Associated with NEXMIF Mutation.

Authors:  Tuğba Alarcon-Martinez; Ayesha Khan; Kenneth A Myers
Journal:  Mol Syndromol       Date:  2019-03-15

4.  Torpedo Maculopathy in a 6-Month-Old Infant: Early Clinical and Optical Coherence Tomography Findings.

Authors:  Caner Kara; İkbal Seza Petriçli
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2017-08-24       Impact factor: 1.402

5.  Torpedo Maculopathy Associated with Choroidal Neovascularization.

Authors:  D Jurjevic; C Böni; D Barthelmes; K Fasler; M Becker; S Michels; J Stemmle; C Herbort; S A Zweifel
Journal:  Klin Monbl Augenheilkd       Date:  2017-05-03       Impact factor: 0.700

6.  The expanding clinical spectrum of torpedo maculopathy.

Authors:  Richard Trevino; Salma Kiani; Praneetha Raveendranathan
Journal:  Optom Vis Sci       Date:  2014-04       Impact factor: 1.973

Review 7.  Clinical spectrum of KIAA2022 pathogenic variants in males: Case report of two boys with KIAA2022 pathogenic variants and review of the literature.

Authors:  Melissa Lorenzo; Irene Stolte-Dijkstra; Patrick van Rheenen; Ronald Garth Smith; Tom Scheers; Jagdeep S Walia
Journal:  Am J Med Genet A       Date:  2018-04-25       Impact factor: 2.802

8.  MULTIMODALITY IMAGING OF TORPEDO MACULOPATHY WITH SWEPT-SOURCE, EN FACE OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.

Authors:  Vasilios P Papastefanou; Clara Vázquez-Alfageme; Pearse A Keane; Mandeep S Sagoo
Journal:  Retin Cases Brief Rep       Date:  2018 Spring

9.  Hyperpigmented torpedo maculopathy.

Authors:  P C Ranjith; Anantharaman Giridhar
Journal:  Indian J Ophthalmol       Date:  2019-02       Impact factor: 1.848

Review 10.  Torpedo Retinopathy.

Authors:  Ramesh Venkatesh; Kushagra Jain; Arpitha Pereira; Naresh Kumar Yadav
Journal:  J Ophthalmic Vis Res       Date:  2020-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.